Status:
NOT_YET_RECRUITING
Fibroblast Growth Factor 23 in Chronic Respiratory Failure
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Fondation Université de Paris
Conditions:
Chronic Respiratory Failure
Eligibility:
All Genders
18+ years
Brief Summary
Fibroblast growth factor 23 (FGF23) is a key hormone of the mineral metabolism produced in bone and acting on the kidney to lower phosphatemia. FGF23 is subject to inactivating proteolytic cleavage wh...
Eligibility Criteria
Inclusion
- Patient informed and not opposed to participating in the research
- Age ≥ 18 years old
- Severe chronic respiratory failure defined by PaO2 \<60 mmHg, whatever the cause, and justifying the initiation of long-term oxygen therapy
- Not yet treated or with stopping oxygen therapy for at least 6 weeks
- Be affiliated with a social security scheme or be a beneficiary of such a scheme
- Be able to understand the interest and the constraints of the study
Exclusion
- Exacerbation of respiratory failure in the 6 weeks prior to inclusion
- Chronic kidney disease defined by a glomerular filtration rate (GFR) estimated by CKD-EPI \<60 mL / min / 1.73m2
- Anemia at the time of inclusion whatever the cause (sickle cell anemia, thalassemia, hemolytic anemia, chronic iron deficiency, others)
- Pregnancy
- Breastfeeding women
- Simultaneous participation in another therapeutic trial
- Patient under guardianship or curatorship
- Patient under medical help from the French government
Key Trial Info
Start Date :
June 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05258370
Start Date
June 1 2023
End Date
May 1 2026
Last Update
April 18 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.